LifeMD 

LifeMD, Inc. is a telehealth company, which engages in offering portfolio of direct-to-patient products and services. It combines virtual medical treatment with prescription medications and over-the-counter products. The firm's network of licensed physicians offers telemedicine services and direct-to-consumer pharmacy to consumers across the United States. The firm's brands include Shapiro, Rex, and Nava. The company was founded in 1987 and is headquartered in New York, NY.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

AGF Management reports stable performance and growth opportunities in Q1 2023

AGF Management delivered stable performance in Q1 2023 with positive net sales and a dividend increase.
While facing challenges in certain business segments, AGF's strong cash position and investment portfolio provide a solid foundation.
Opportunities lie in capital allocation strategies, growth initiatives, and enhancing performance in key business areas.
Overall, AGF's focus on shareholder returns and strategic investments positions the company for future growth and success.

LifeMD surpasses Q1 expectations, eyes growth amid challenges

LifeMD's Q1 2023 performance exceeded expectations, driven by strong revenue and EBITDA results.
The company's strategic initiatives, including debt financing and AI integration, position it for growth.
Challenges lie in maintaining growth momentum, managing costs, and optimizing EBITDA margins.
Opportunities in partnerships, telehealth, and patient value enhancement offer avenues for future growth.

LifeMD reports strong Q2 performance and raises revenue guidance

LifeMD's Q2 performance reflects operational strength, revenue growth, and strategic initiatives driving positive results and financial stability.
While facing challenges in adjusted EBITDA guidance due to investments, the company maintains a strong position with record revenues and subscriber growth.
Opportunities for growth and expansion exist through the weight management program, partnerships, and focus on existing health care businesses.

LifeMD reports record Q3 revenue and profitability, eyes growth opportunities

LifeMD's Q3 results reflect a successful quarter marked by strong revenue, profitability, and subscriber growth. The company's focus on strategic initiatives and positive outlook for 2024 indicate a promising future with plans to accelerate momentum and deliver impressive results.

LifeMD reports record 2023 performance, eyes growth in weight management

LifeMD's strong performance in 2023 sets the stage for continued growth and profitability. The company's strategic focus on diversification, market expansion, and cost management positions it well for future success. Challenges in subscriber numbers and commercial partnerships require attention, but overall, LifeMD is on a positive trajectory.

LifeMD excels in Q2 with telehealth growth, WorkSimpli rebounds

LifeMD demonstrated robust performance in Q2 2024, driven by the success of its core telehealth business and strategic initiatives.
While facing challenges, WorkSimpli is making progress towards regaining peak profitability by addressing competitive and executional issues.
Opportunities lie in expanding service offerings, enhancing collaborations, and leveraging upcoming launches to drive growth and profitability for LifeMD.
Strategic focus on innovation, efficiency, and market differentiation positions LifeMD well for sustained success and revenue growth in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LifeMD, Inc. is a telehealth company, which engages in offering a portfolio of direct-to-patient products and services. The firm combines virtual medical treatment with prescription medications and over-the-counter products. It operates through the Telehealth and WorkSimpli segments. The company was founded by Justin Schreiber on May 24, 1994 and is headquartered in New York, NY.

LFMD expands its men's health services with TestoRx, offering convenient testosterone therapy and alternative treatments for low testosterone via telehealth.

LifeMD Shares Decline Even After the Launch of Testosterone Therapy

NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.5546875 per share.

LifeMD® Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

LifeMD's Q2 2024 earnings were mixed, with management failing to monetize the non-core WorkSimpli asset, leading me to assign it no value. Despite management's over-promising, LifeMD's telehealth and GLP1 offerings show significant potential, with the stock priced at 14x forward EBITDA. I have revised my price target from $20 to $15 per share by summer 2025, due to management's credibility issues and uncertainties in GLP1 prospects.

LifeMD: Selling WorkSimpli Could Be A Catalyst

NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that management will be participating in the following investor conferences during the month of September:

LifeMD to Participate in Three Investor Conferences During September

LifeMD, Inc. (NASDAQ:LFMD ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Justin Schreiber – Chairman and Chief Executive Officer Marc Benathen – Chief Financial Officer Conference Call Participants David Larsen – BTIG Steve Dechert – KeyBanc William Wood – B. Riley Securities Sarah James – Cantor Yi Chen – H.C.

LifeMD, Inc. (LFMD) Q2 2024 Earnings Call Transcript

LifeMD, Inc. (LFMD) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.23 per share a year ago.

LifeMD, Inc. (LFMD) Reports Q2 Loss, Tops Revenue Estimates

Revenue increased 41% year-over-year to $50.7 million with telehealth revenue up 67% Telehealth achieved standalone profitability one quarter ahead of guidance, with adjusted EBITDA of $820,000 Weight management subscribers exceeded 60,000 as of June 30, 2024 Adjusted EBITDA increased 44% to $2.5 million Cash of $35.7 million as of June 30, 2024, and positive net cash flow in three of the last four quarters Conference call begins at 4:30 p.m. Eastern time today NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today reported financial results for the three and six months ended June 30, 2024.

LifeMD Reports Second Quarter 2024 Results

LifeMD is positioned as a high-growth telehealth play with a focus on GLP-1 weight management treatments. The company is guiding for 35% revenue growth in 2024. Its core telehealth business is expected to grow at least 43%. Non-core software subsidiary WorkSimpli may be spun off in the next 6 to 12 months, while the company is on track for GAAP profitability next year.

LifeMD: High Growth GLP-1 Telehealth Play At A Discount

Health Catalyst Inc

Teladoc

Healthcare portfolios include telehealth stocks, notably after the COVID-19 pandemic, which increased global telemedicine usage, demonstrating their importance for lockdowns and other social isolation scenarios. The worldwide telehealth market was $122.2 billion in 2023 and is anticipated to rise 28.4% annually from 2024 to 2032.

3 Overlooked Telehealth Stocks Poised for a Comeback

NEW YORK, June 25, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD/LFMDP), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.5546875 per share.

LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

Identifying investment opportunities in the healthcare sector involves research on trends and next-gen tech. LifeMD offers telehealth services and weight management programs, positioned for growth in the underserved obesity market. Risks include regulatory changes, competition, cash position, and the potential need for additional funding.

LifeMD: Pairing GLP-1 Agonists With Virtual Healthcare

NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that management will be participating in the Truist Securities Healthcare Disruptors & Digital Health Summit taking place June 25-26, 2024 at the Lotte New York Palace. Justin Schreiber, Chief Executive Officer of LifeMD, will be joining a panel discussion titled “Weight Management/Diabetes Care: Tools to Manage Cost vs Benefit.” Management will also be holding one-on-one meetings with investors.

LifeMD to Participate in the Truist Securities Healthcare Disruptors & Digital Health Summit

LifeMD Inc. NASDAQ: LFMD is a leading telehealth provider operating an end-to-end virtual healthcare platform. LifeMD operates a direct-to-consumer (DTC) model focused on offering on-demand primary care services to consumers.

LifeMD Can Surge on Its GLP-1 Offerings

LifeMD, Inc. (NASDAQ:LFMD ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Justin Schreiber - Chairman & Chief Executive Officer Marc Benathen - Chief Financial Officer Conference Call Participants David Larsen - BTIG Sarah James - Cantor William Wood - B. Riley Securities Alex Fuhrman - Craig-Hallum Operator Good afternoon.

LifeMD, Inc. (LFMD) Q1 2024 Earnings Call Transcript

NEW YORK , May 8, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating LifeMD, Inc. (NASDAQ: LFMD) on behalf of the company's shareholders.  The investigation seeks to determine whether LifeMD's directors breached their fiduciary duties in connection with recent corporate actions.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of LifeMD, Inc. (NASDAQ: LFMD)

Evolus

Sana Biotechnology

Expro Group Holdings NV

Notable companies to have witnessed solid earnings acceleration as of now are Sana Biotechnology (SANA), LifeMD (LFMD), Evolus (EOLS) and Expro Group Holdings (XPRO).

4 Stocks to Keep a Tab on for Amazing Earnings Acceleration

LifeMD and Withings Health Solutions partnership exemplifies the potential of digital health technology to transform virtual patient care and improve outcomes LifeMD and Withings Health Solutions partnership exemplifies the potential of digital health technology to transform virtual patient care and improve outcomes

LifeMD Becomes the First Virtual Primary Care Provider to Elevate GLP-1 Patient Care with Real-time, At-Home Monitoring of Blood Pressure and Body Composition

NEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced the appointment of Calum MacRae, M.D., Ph.D., a clinician, researcher and educator at Harvard Medical School, as an independent member of its Board of Directors.

LifeMD Appoints Dr. Calum MacRae to its Board of Directors

NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three months ended March 31, 2024 after the close of the U.S. financial markets on May 8, 2024 and will host a conference call beginning at 4:30 p.m. Eastern time.

LifeMD to Report First Quarter 2024 Financial Results on May 8

NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that management will be participating in the 23rd Annual Needham Virtual Healthcare Conference taking place April 8-11, 2024. Management will be presenting a corporate overview and will be holding one-on-one meetings with investors.

LifeMD to Participate in the 23rd Annual Needham Virtual Healthcare Conference

LifeMD Inc. NASDAQ: LFMD provides telehealth services to consumers in the United States. The medical sector company operates many telehealth brands, including men's telehealth brands RexMD and ShapiroMD, NavaMD female dermatology telehealth, Cleared Allergy Clinic, and LifeMD Primary Care.

LifeMD Shares Come Back to Life on GLP-1 Business Growth

Global X Telemedicine & Digital Health ETF

Hims & Hers Health

With the growing demand for telemedicine, the market could be worth about $450 billion by the time 2032 rolls around. That's according to Emergen Research.

3 Stocks That Could Benefit from the Rise of Telemedicine

LifeMD reported impressive revenue growth, with a 60% increase to $44.9 million, driven by a 90% increase in telehealth revenues. Weight management subscribers more than doubled sequentially, resulting greater than 100% revenue growth quarter over quarter from this segment. Management raised its 2024 revenue forecast to at least $200 million, indicating strong growth potential and the likelihood of analyst upward revisions.

LifeMD: Results And Guidance Point To Continued Strength In Weight Management Program

Eli Lilly

Novo Nordisk

Weightwatchers International Inc.

WW International Inc. NASDAQ: WW (WeightWatchers) has had a disastrous 2024, with its shares collapsing 66.7% year-to-date (YTD). The company made a praiseworthy strategic pivot in 2023, acquiring Sequence Inc. to enter into the GLP-1 clinical weight loss space, gaining the ability to prescribe medications like Novo Nordisk A/V NYSE: NVO owned Ozempic and Wegovy and Eli Lilly& Co. NYSE: LLY GLP-1 agonists like Mounjaro and Zepbound.

Can WeightWatchers Regain Its Mojo after Oprah Steps Down?

LifeMD, Inc. (NASDAQ:LFMD ) Q4 2023 Earnings Conference Call March 11, 2024 4:30 PM ET Company Participants Justin Schreiber - Chairman and CEO Marc Benathen - CFO Conference Call Participants David Larsen - BTIG William Wood - B. Riley Alex Fuhrman - Craig-Hallum Ilya Zubkov - Freedom Broker Yi Chen - H.C.

News for LifeMD Stock (LFMD)